Epitope Diagnostics Inc. New COVID-19 IgG and IgM ELISA Featured in Icelandic Study on Humans Immune Response to SARS-CoV-2 Exposure
A study has recently been published in the New England Journal of Medicine titled Humoral Immune Response to SARS-CoV-2 in Iceland by D.F. Gudbjartsson, et. al. This study takes a look at the semi-long term immune response of the COVID-19 respiratory infection. 30,576 patient samples were tested for both IgG and IgM antibodies using both q-PCR and ELISA methods. The ELISA’s used in this study were the Coronavirus COVID-19 IgG ELISA Assay and Coronavirus COVID-19 IgM ELISA Assay Kit offered by Eagle Biosciences. The results of this study showed that IgM anti-N antibody levels increased rapidly soon after diagnosis and then fell rapidly and were generally not detected after 2 months. IgG anti-N and anti-S1 antibody levels increased during the first 6 weeks after diagnosis and then decreased slightly, indicating that antiviral antibodies against SERS-CoV-2 did not decline within 4 months after diagnosis. With respect to clinical characteristics, antibody levels were most strongly associated with hospitalization and clinical severity, followed by clinical symptoms such as fever, maximum temperature reading, cough, and loss of appetite. Severity of these individual symptoms, with the exception of loss of energy, was associated with higher antibody levels.
More research still needs to be conducted to understand the full immune response over time. However, this is a great step in the development of how this virus works and how the world will be able to overcome it.
To learn more and read the full publication, click here.
To view Eagle Biosciencs extensive selection of SARS-CoV-2 Assays and other products, click here